Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Hypotension Article
This is a selection made from among articles on Drug Treatment Hypotension. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
Alcohol Rehab and Dual Diagnosis Treatment Today
By Jonathan Huttner
Alcohol Rehab and Dual Diagnosis Treatment Individuals who struggle with both mental illness and a substance abuse problem face special challenges in alcohol rehab. A quality alcohol rehab program recognizes the unique challenges of dually diagnosed clients and offers dual diagnosis treatment in their alcohol rehab center.
Dual Diagnosis Treatment Philosophy in a Alcohol Rehab Program
In years past, alcohol rehabs actually treated mental illness and substance abuse separately. It would not be uncommon to see a patient enter a alcohol rehab for alcohol rehabilitation and then be transferred to a mental health center for dual diagnosis treatment. Today, the quality alcohol rehabs treat alcoholism and psychiatric disorders concurrently and with much better results.
Key Elements in an Alcohol Rehab Program for Dual Diagnosis Treatment An alcohol rehabilitation program designed to treat dual diagnosis must have a psychiatrist that is trained in addiction medicine. In addition to the psychiatrist the staff in the alcohol treatment center must have a thorough understanding of mental health disorders and how to treat them. While alcohol rehabilitation can move along at a steady pace, dual diagnosis treatment is much more gradual. Most people who are admitted to an alcohol rehab program and are dually diagnosed will generally be able to follow the overall guidelines of the alcohol rehab center.
If it becomes apparent they are too impaired from a mental health perspective, they may require transfer from the alcohol rehab with dual diagnosis treatment services to an actual psychiatric hospital.For additional information relating to an effective dual diagnosis treatment center or quality alcohol rehabs, please go to www.dual-diagnosis-treatment-center.com or call the national alcohol rehabilitation helpline at 1-800-511-9225.
Jonathan Huttner is one of the founders of a national addiction treatment helpline 1-800-511-9225, which can help you locate effective treatment anywhere in the United States.
Article Source: http://EzineArticles.com/?expert=Jonathan_Huttner
http://EzineArticles.com/?Alcohol-Rehab-and-Dual-Diagnosis-Treatment-Today&id=632348
Drug Treatment Hypotension Specific links
Drug Treatment Hypotension News
FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine, Pfizer’s Novel Investigational ...
Pfizer Inc. announced today that the United States Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee voted on Pfizer’s clinical data package for tafamidis meglumine.
Read more...Chelsea Therapeutics Completes End-of-Review Meeting With FDA for Northera(TM) (droxidopa) Capsules New Drug Application
Chelsea Proposing to Change Primary Endpoint and Submit Dizziness Data From Ongoing Study 306B to Support Resubmission of Northera NDA for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension...
Read more...Press Release
Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted on Pfizer’s clinical data package for tafamidis meglumine.
Read more...Latuda® (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of ...
Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved an expanded dose range for LATUDA in the treatment of adult patients with schizophrenia.
Read more...Shorter Timeframe, More Risky
Chelsea gets updated information from the FDA.
Read more...Chelsea eyes narrower target for Northera (Weekend Rounds)
Life science current events this week include: a narrower target for Chelsea's Northera hypotension drug, Covidian collaboration with Maya Medical, Colbert's take on Accretive scandal, Lilly Ventures-led pharmaceutical startup
Read more...Chelsea Therapeutics to modify Northera study, resubmit NDA in 2013
Chelsea Therapeutics (NASDAQ:CHTP), regrouping from orphan drug Northera’s failure to secure regulatory approval, now plans to resubmit a new drug application in early 2013 with data from a modified phase 3 study. The Charlotte, North Carolina drug developer announced the plans following its meeting with the U.S. Food and Drug Administration to discuss the complete response [...]
Read more...Pomerantz Law Firm Reminds Shareholders of Chelsea Therapeutics International Ltd. of Upcoming Deadline -- CHTP
NEW YORK -- Shareholders of Chelsea Therapeutics International Ltd. ("Chelsea" or the "Company") are reminded of the securities class action filed against Chelsea and certain of its ...
Read more...PETA, feds team up for lifesaving new toxicity test
( People for the Ethical Treatment of Animals ) PETA works with industry and government scientists to spare lives of tens of thousands of animals through new shellfish toxicity test.
Read more...CHTP might seek limited Northera approval, meets with FDA this month
Chelsea Therapeutics (NASDAQ:CHTP) won’t meet with regulators until later this month to discuss its orphan drug Northera but the company is already staking out scenarios of a more limited approval for the drug. If results of an ongoing phase 3 study don’t support the durability of Northera’s effect over time, the company said in its quarterly [...]
Read more...